Back to homepage
MyChart

Cardiac Clinical Trials Underway at Holy Cross Health

February 14, 2023
Cardiac Health

By: Staff Writer

Categories: Heart Health

Holy Cross Health cardiologists are leading several heart-related clinical trials. As a leader in clinical cardiac research, Holy Cross Health continues to expand efforts in offering innovative research studies to ensure the best possible long-term outcomes for patients in the community.

"We have always been on the leading-edge of technology and providing excellent care," said Holy Cross Health President and CEO Mark Doyle. "We are continually providing increased access to studies and trials that will lead to positive outcomes for patients."

Here's a list of the heart studies underway:

  • evaluating the effect of in-hospital initiation of Dapagliflozin on clinical outcomes in patients who have been stabilized during hospitalization for Acute HF;
  • collecting sensor and heart failure event data that will be used to develop and test new diagnostic features for the insertable cardiac monitor ICM systems;
  • evaluating the efficacy and safety of AZD4831 in participants with heart failure with left ventricular ejection fraction;
  • studying the safety and effectiveness of cardiac contractility modulation therapy in subjects with symptomatic heart failure;
  • evaluating the efficacy and safety of the sGC Stimulator Vericiguat/MK-1242 in adults with stable heart failure with reduced ejection fraction;
  • Acute ACS to investigate the efficacy and safety of CSL112 in subjects with Acute Coronary Syndrome;
  • Recent ACS to investigate post-discharge care pathway for patients with a recent acute coronary syndrome who have elevated LDL-C despite being on maximally tolerated statin therapy following an ACS will be randomized to receive one of our new LDL-C lowering therapies or usual care
  • Non interventional trial: The number of recurrent HF readmissions. [Monitoring period: 12 months] [ Time Frame: 12 Months ]Determine if HEMOTAG and symptom guided treatment during a follow-up period results in decreased rate of heart failure re-hospitalizations.
  • Pfizer C3651101; Study of the effects of Ponsegromabon Health Related quality of life and safety in patients with heart failure.
  • SEGA trial: Neuro/Cardio: Sedation vs. general anesthesia for endovascular therapy in acute ischemic stroke.

Learn more at https://www.holy-cross.com/find-a-service-or-specialty/heart-and-vascular-care/clinical-trials-and-research/

  More articles

Staff Writer